share_log

8-K: Applied DNA Announces Fourth Quarter and Fiscal Year 2024 Financial Results, Announces Strategic Restructuring to Prioritize the Manufacture of Critical Starting Materials for Genetic Medicines

8-K: Applied DNA Announces Fourth Quarter and Fiscal Year 2024 Financial Results, Announces Strategic Restructuring to Prioritize the Manufacture of Critical Starting Materials for Genetic Medicines

8-K:Applied DNA公布第四季度和2024财年财务业绩,宣布战略重组,优先生产基因药物的关键起始材料
美股SEC公告 ·  2024/12/18 05:14

Moomoo AI 已提取核心信息

Applied DNA Sciences announced Q4 and FY2024 results, along with a strategic restructuring to prioritize manufacturing critical materials for genetic medicines. The company is pursuing divestiture of its CertainT platform and targeting 15% operating expense reductions by Q2 FY2025.Q4 revenues were $813,000, up from $780,000 in Q4 FY2023. FY2024 revenues fell to $3.4 million from $13.4 million, due to decreased COVID-19 testing demand. Net loss for FY2024 was $7.1 million. Cash and equivalents totaled $6.4 million as of September 30, 2024, with an additional $5.8 million raised in October.The company promoted Judith Murrah to President and Clay Shorrock to President of LineaRx subsidiary. It expects to complete its GMP manufacturing facility by January 9, 2025, with $4-16 million annual revenue capacity. GMP production for existing customers' clinical trials is anticipated in H1 2025.
Applied DNA Sciences announced Q4 and FY2024 results, along with a strategic restructuring to prioritize manufacturing critical materials for genetic medicines. The company is pursuing divestiture of its CertainT platform and targeting 15% operating expense reductions by Q2 FY2025.Q4 revenues were $813,000, up from $780,000 in Q4 FY2023. FY2024 revenues fell to $3.4 million from $13.4 million, due to decreased COVID-19 testing demand. Net loss for FY2024 was $7.1 million. Cash and equivalents totaled $6.4 million as of September 30, 2024, with an additional $5.8 million raised in October.The company promoted Judith Murrah to President and Clay Shorrock to President of LineaRx subsidiary. It expects to complete its GMP manufacturing facility by January 9, 2025, with $4-16 million annual revenue capacity. GMP production for existing customers' clinical trials is anticipated in H1 2025.
Applied DNA Sciences 宣布了2024财年第四季度及全年业绩,并进行了战略重组,以优先制造用于基因药物的关键材料。公司正在寻求出售其Certaint平台,并计划在2025财年第二季度将运营费用减少15%。第四季度营业收入为813,000美元,较2023财年第四季度的780,000美元有所增长。2024财年的收入因新冠疫情检测需求减少而降至340万美元,而之前为1340万美元。2024财年的净亏损为710万美元。到2024年9月30日,公司现金及现金等价物总计为640万美元,另外在10月份筹集了580万美元。公司提升了Judith Murrah为总裁,并任命Clay Shorrock为LineaRx子公司的总裁。预计将在2025年1月9日之前完成其GMP制造设施,年营业收入能力在400万到1600万美元之间。预计在2025年上半年为现有客户的临床试验进行GMP生产。
Applied DNA Sciences 宣布了2024财年第四季度及全年业绩,并进行了战略重组,以优先制造用于基因药物的关键材料。公司正在寻求出售其Certaint平台,并计划在2025财年第二季度将运营费用减少15%。第四季度营业收入为813,000美元,较2023财年第四季度的780,000美元有所增长。2024财年的收入因新冠疫情检测需求减少而降至340万美元,而之前为1340万美元。2024财年的净亏损为710万美元。到2024年9月30日,公司现金及现金等价物总计为640万美元,另外在10月份筹集了580万美元。公司提升了Judith Murrah为总裁,并任命Clay Shorrock为LineaRx子公司的总裁。预计将在2025年1月9日之前完成其GMP制造设施,年营业收入能力在400万到1600万美元之间。预计在2025年上半年为现有客户的临床试验进行GMP生产。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息